Delving into the Latest Updates on BAY-1211163 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms-

Target

GCs

Action

stimulants

Mechanism

Guanylate cyclase stimulants

Therapeutic Areas

Respiratory Diseases

Active Indication-

Inactive Indication

Respiratory Distress Syndrome, Acute

Originator Organization

Bayer AG

Active Organization-

Inactive Organization

Bayer AG

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Safety and Tolerability of Adaptive Escalating Multiple Doses (Three Times Daily) of a Soluble Guanylate Cyclase (sGC) Activator Inhale, BAY 1211163, as Inhalation in Intubated and Mechanically Ventilated Adult Patients With Moderate and Severe Acute Respiratory Distress Syndrome (ARDS). A Pilot (Phase Ib), First in Patient, Open Label Study

With this study researchers want to find the highest safe dose of the soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 and how safe and well the study drug works. Furthermore researchers want to gather information on the way the body absorbs, distributes and gets rid of the study drug given as increasing multiple doses by inhalation to patients who cannot breathe by their own and suffer from a type of lung failure that causes fluid to build up in the lungs making breathing difficult (ARDS)

Start Date24 Nov 2020

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with BAY-1211163

Login to view more data

100 Translational Medicine associated with BAY-1211163

Login to view more data

100 Patents (Medical) associated with BAY-1211163

Login to view more data

100 Deals associated with BAY-1211163

Login to view more data